Dyadic International Receives Second Nasdaq Delisting Notice, Citing Financial Metrics Deficiency
DYAI is trading near its 52-week low of $0.655 (3.9% above the low) on elevated volume (2.9× avg).
Summary
Dyadic International received a second, separate deficiency notice from Nasdaq for failing to meet minimum financial listing requirements, compounding its existing minimum bid price issue and increasing delisting risk.
Key Events · Corporate Governance and Compliance · DYAI
-
Second Nasdaq Deficiency Notice Received
On March 27, 2026, Dyadic International received a deficiency notice from Nasdaq Listing Qualifications staff, citing non-compliance with Nasdaq Listing Rule 5550(b).
-
Failure to Meet Financial Listing Requirements
The deficiency is due to not maintaining at least $2.5 million in stockholders' equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
-
Compounding Delisting Risk
This new deficiency is separate from the previously disclosed minimum bid price deficiency (Rule 5550(a)(2)), meaning the company now faces two distinct threats to its Nasdaq listing.
-
Compliance Plan Deadline
The company has 45 calendar days, until May 11, 2026, to submit a plan to regain compliance for the new deficiency, with a potential cure period of up to 180 days.
Analysis · DYAI · Life Sciences
This 8-K filing reveals a critical development for Dyadic International, as it has received a second, distinct deficiency notice from Nasdaq. This new notice, under Rule 5550(b), indicates the company's failure to meet minimum requirements for stockholders' equity, market value of listed securities, or net income. This comes on top of the previously disclosed minimum bid price deficiency (Rule 5550(a)(2)). Facing two separate delisting threats significantly elevates the risk of the company's common stock being removed from the Nasdaq Capital Market, especially as the stock is currently trading near its 52-week low. While the company has 45 days to submit a compliance plan for this new deficiency, and a potential cure period, the dual non-compliance signals severe financial and operational challenges. Investors should be aware of the heightened uncertainty regarding the company's continued listing.
At the time of this filing, DYAI was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.7M. The 52-week trading range was $0.65 to $1.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.